

HOLD TP: Rs 2,266 | ∀ 1%

MPHASIS

Technology & Internet

08 May 2024

Modest growth; BFSI yet to pick up

- Regional banks and mortgages business will continue to draw down the overall BFSI segment
- Expertise in Microsoft Dynamics and Salesforce through acquisition likely to impact positively in improving deal pipeline
- We assume coverage on Mphasis with a HOLD rating and TP of Rs 2,266 based on 22x P/E on FY26E EPS (in line with current P/E)

Saptarshi Mukherjee research@bobcaps.in

Growth headwinds expected in FY25: The company's revenue performance remained volatile over the last few quarters. Banking forms ~47% of the total portfolio, majorly relying on higher discretionary spending, which is impacting near-term growth visibility. Mortgage business (Digital Risk) and DXC channel impacted revenue by 10% over the last two years. We believe higher exposure in regional banks, coupled with uncertainty over US interest rates, will create continued headwinds in critical/major accounts (Top-10 accounts). Tight budgets, insourcing and layoffs likely to disrupt growth for Mphasis, in our view. In this situation, the company needs better discretionary spending and share gains in vendor consolidation.

Reshuffle/hire in senior management team: The company has hired Ashish Devalekar to head the Europe operations and Anurag Bhatia has been transferred to the BPS business.

Building enterprise business through M&A: Mphasis is building capabilities in Microsoft Dynamics/Salesforce through acquisitions of eBecs and Silverline. The company is trying to improve the large client mining through new services offerings. Mphasis has partnered with Kore.Al especially for the infusion of generative Al and the implementation of the product to improve the company's revenue stream.

Moderated deal TCV but stability in margin remains intact: FY24 revenue stood at USD 1.6bn, down 16% in BFS but non-BFS was up 5% YoY. EBIT margin in Q4 was 14.9% (including Silverline integration cost of 110bps QoQ). Margin guidance stood at 14.6-16% in FY25. New total contract value stood at USD 177mn in Direct business and 77% of the deal wins are coming from Next-Gen services.

Valuation outlook: Despite weakness in the mortgage business and tight budgets in key verticals/top accounts, we expect reduction in near-term leakage and recovery in Digital Risk. Mphasis trades at 25.2x FY25E and 22.2x FY26E EPS. We assume coverage with HOLD rating with a TP of Rs 2,266 based on 22x P/E of FY26E EPS in line with current P/E.

Key changes

Target	Rating
▼	∢ ▶

Ticker/Price	MPHL IN/Rs 2,287
Market cap	US\$ 5.2bn
Free float	40%
3M ADV	US\$ 15.6mn
52wk high/low	Rs 2,838/Rs 1,808
Promoter/FPI/DII	52%/29%/14%

Source: NSE | Price as of 7 May 2024

Key financials

FY24A	FY25E	FY26E
1,32,785	1,41,349	1,48,186
24,220	26,291	28,896
15,548	17,125	19,469
82.4	90.6	103.0
82.4	91.2	105.5
18.6	18.7	19.8
27.7	25.2	22.2
17.5	16.2	14.8
(5.3)	9.9	13.7
	1,32,785 24,220 15,548 82.4 82.4 18.6 27.7 17.5	1,32,785 1,41,349 24,220 26,291 15,548 17,125 82.4 90.6 82.4 91.2 18.6 18.7 27.7 25.2 17.5 16.2

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE






Fig 1 - Quarterly performance

(Rs mn)	Q4FY24	Q3FY23	Q4FY23	QoQ (%)	YoY (%)
US\$ Revenue	411	402	412	2.1	(0.3)
INR Revenue	34,150	33,507	33,893	1.9	0.8
EBIT	5,080	4,972	5,152	2.2	(1.4)
PAT	3,932	3,736	4,052	5.2	(3.0)
EBIT Margin (%)	14.9	14.8	15.2	4bps	(33bps)
PAT Margin (%)	11.5	11.1	12.0	36bps	(44bps)


Source: Company, BOBCAPS Research

Fig 2 - Employee metrics




Source: Company, BOBCAPS Research

Fig 4 - Revenue by geography




Source: Company, BOBCAPS Research

Fig 6 - Net new deal TCV (Direct business)




Source: Company, BOBCAPS Research | TCV: Total contract value

Fig 3 - Client composition



Source: Company, BOBCAPS Research

Fig 5 - Revenue by service type



Source: Company, BOBCAPS Research



Valuation outlook

Despite weakness in the mortgage business and tight budgets in key verticals/top accounts, we expect reduction in near-term leakage and recovery in Digital Risk. Mphasis trades at 25.2x FY25E and 22.2x FY26E EPS. We assume coverage with HOLD rating with a TP of Rs 2,266 based on 22x P/E of FY26E EPS (in line with current P/E.).

Risks

- Decrease in interest rates may lead to higher deal wins in BFSI, and,
- an elongated decision-making cycle could lead to lower transformational deal wins.



Financials

Income Statement	EV004	EV004	EV044	FVACE	E)/00=
Y/E 31 Mar (Rs mn)	FY22A	FY23A	FY24A	FY25E	FY26E
Total revenue	1,19,614	1,37,984	1,32,785	1,41,349	1,48,186
EBITDA	21,175	24,339	24,220	26,291	28,896
Depreciation	2,906	3,253	4,106	4,240	4,149
EBIT	18,269	21,086	20,114	22,050	24,747
Net interest inc./(exp.)	0	0	0	0	0
Other inc./(exp.)	861	645	570	700	1,040
Exceptional items	0	0	0	0	0
EBT	19,130	21,731	20,684	22,750	25,787
Income taxes	4,821	5,351	5,136	5,626	6,318
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	14,309	16,380	15,548	17,125	19,469
Adjustments	0	0	0	0	0
Adjusted net profit	14,309	16,380	15,548	17,125	19,469
Balanca Chast					
Balance Sheet Y/E 31 Mar (Rs mn)	FY22A	FY23A	FY24A	FY25E	FY26E
Accounts payables	8,496	8,640	7,983	8,094	8,269
Other current liabilities	16,956	14,707	28,536	30,632	32,330
Provisions	2,272	2,797	3,480	3,873	4,060
Debt funds	6,900	7,145	9,173	9,173	9,173
Other liabilities	3,507	3,458	4,184	4,184	4,184
Equity capital	1,878	1,884	1,890	1,890	1,890
Reserves & surplus	67,553	77,464	86,056	92,906	99,720
Shareholders' fund		79,348		92,900	
	69,431	1,16,095	87,946 1,41,302		1,01,610
Total liab. and equities	1,07,561			1,50,751	1,59,625
Cash and cash eq. Accounts receivables	8,268 22,269	10,441	8,049	9,124	10,943
		26,540	27,027	29,819	32,073
Inventories	0	0	0	0	40.000
Other current assets	12,896	12,332	10,015	10,456	10,962
Investments	19,356	17,620	30,994	35,994	39,994
Net fixed assets	8,693	9,718	9,215	9,357	9,653
CWIP	110	55	137	137	137
Intangible assets	29,043	31,149	46,588	46,588	46,588
Deferred tax assets, net	6,925	8,240	9,276	9,276	9,276
Other assets	0	0	0	0	0
Total assets	1,07,561	1,16,095	1,41,302	1,50,751	1,59,625
Cash Flows					
Y/E 31 Mar (Rs mn)	FY22A	FY23A	FY24A	FY25E	FY26E
Cash flow from operations	17,157	14,618	21,797	20,032	21,879
Capital expenditures	(1,192)	(1,112)	(916)	(4,382)	(4,446)
Change in investments	1,085	1,354	(11,898)	(5,000)	(4,000)
Other investing cash flows	(2,713)	1,582	(12,006)	700	1,040
Cash flow from investing	(2,820)	1,825	(24,821)	(8,682)	(7,406)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	(16,164)	(13,517)	(13,120)	0	0
Interest expenses	14,919	8,245	23,887	0	0
Dividends paid	(465)	(478)	(569)	(10,275)	(12,655)
Other financing cash flows	0	0	0	0	(_,,,,,,
					(40 CEE)
Cash flow from financing	(1,710)	(5.750)	70.198		
Cash flow from financing Chg in cash & cash eq.	(1,710) 12,627	(5,750) 10,693	10,198 7,174	(10,275) 1,075	(12,655) 1,818

Per Share Y/E 31 Mar (Rs)	FY22A	FY23A	FY24A	FY25E	FY26E
Reported EPS	76.4	87.1	82.4	90.6	103.0
Adjusted EPS	76.4	87.1	82.4	90.6	103.0
Dividend per share	42.1	47.8	45.2	54.4	66.9
Book value per share	371.6	420.9	465.2	501.5	537.5
DOOK Value per Stiate	37 1.0	420.3	403.2	301.3	337.0
Valuations Ratios					
Y/E 31 Mar (x)	FY22A	FY23A	FY24A	FY25E	FY26E
EV/Sales	3.6	3.1	3.2	3.0	2.9
EV/EBITDA	20.3	17.6	17.5	16.2	14.8
Adjusted P/E	29.9	26.3	27.7	25.2	22.2
P/BV	6.2	5.4	4.9	4.6	4.3
DuPont Analysis					
Y/E 31 Mar (%)	FY22A	FY23A	FY24A	FY25E	FY26
Tax burden (Net profit/PBT)	74.8	75.4	75.2	75.3	75.
Interest burden (PBT/EBIT)	104.7	103.1	102.8	103.2	104.
EBIT margin (EBIT/Revenue)	15.3	15.3	15.1	15.6	16.
Asset turnover (Rev./Avg TA)	119.4	123.4	103.2	96.8	95.
Leverage (Avg TA/Avg Equity)	1.5	1.5	1.5	1.6	1.0
Adjusted ROAE	21.2	22.0	18.6	18.7	19.8
Datia Amalusia					
Ratio Analysis Y/E 31 Mar	FY22A	FY23A	FY24A	FY25E	FY26E
	FTZZA	FIZSA	F1Z4A	FIZOE	F 1 20E
YoY growth (%)	23.0	15.4	(2.0)	6.4	4
Revenue			(3.8)		4.8
EBITDA	17.5	14.9	(0.5)	8.6	9.9
Adjusted EPS	17.3	14.0	(5.3)	9.9	13.
Profitability & Return ratios (%)		47.0	40.0	40.0	40
EBITDA margin	17.7	17.6	18.2	18.6	19.
EBIT margin	15.3	15.3	15.1	15.6	16.
Adjusted profit margin	12.0	11.9	11.7	12.1	13.
Adjusted ROAE	21.2	22.0	18.6	18.7	19.
ROCE	19.9	21.0	17.5	17.3	18.4
Working capital days (days)					
Receivables	46	65	74	73	70
	0	0	0	0	
Inventory			0.0	0.0	
Payables	67	59	69	99	10
Payables Ratios (x)	67	59			
Payables			14.0	99	10

Adjusted debt/equity 0.0 0.0

Source: Company, BOBCAPS Research | Note: TA = Total Assets

1.6

NA

1.9

NA

1.1

NA

0.0

1.2

NA

0.0

1.2

NA

0.0

Current ratio

Net interest coverage ratio



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: BOB Capital Markets Limited

Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051

SEBI Research Analyst Registration No: INH000000040 valid till 03 February 2025

Brand Name: BOBCAPS

Trade Name: www.barodaetrade.com





Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): MPHASIS (MPHL IN)



 $B-Buy,\,H-Hold,\,S-Sell,\,A-Add,\,R-Reduce$

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

MPHASIS



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct his report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.